Not a comparable situation. There was a huge warehouse of pent-up demand when Sovaldi launched and, again, when Harvoni launched (and IFN was no longer needed for on-label treatment of GT1).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.